$APLS
Apellis Pharmaceuticals, Inc. Stock $apls

$apls Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-Q Financial Statement

#000156459021055235 Filed on November 08, 2021

Income Statement

Concept	2021 Q3	2020 Q3	2020 Q2
Revenue	$5.650M	$646.0K	$0.00
YoY Change	774.61%
Cost Of Revenue	$149.0K
YoY Change
Gross Profit	$5.501M
YoY Change
Gross Profit Margin	97.36%
Selling, General & Admin	$74.18M	$57.00M	$46.70M
YoY Change	30.15%	206.45%	264.84%
% of Gross Profit	1348.55%
Research & Development	$87.73M	$93.21M	$87.09M
YoY Change	-5.87%	81.62%	71.79%
% of Gross Profit	1594.86%
Depreciation & Amortization	$282.0K	$190.0K	$90.00K
YoY Change	48.42%	216.67%	80.0%
% of Gross Profit	5.13%
Operating Expenses	$133.6M	$130.2M	$115.5M
YoY Change	2.65%	153.7%	127.83%
Operating Profit	-$128.1M	-$129.6M	-$115.5M
YoY Change	-1.09%	85.21%	81.97%
Interest Expense	-$6.357M	-$6.100M	-$3.100M
YoY Change	4.21%	-1320.0%	-60.26%
% of Operating Profit
Other Income/Expense, Net	-$117.0K	-$16.00K	$5.000K
YoY Change	631.25%	-73.77%	-97.5%
Pretax Income	-$195.6M	-$135.7M	-$118.6M
YoY Change	44.12%	94.41%	66.81%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$195.6M	-$135.7M	-$118.6M
YoY Change	44.12%	94.34%	66.85%
Net Earnings / Revenue	-3461.43%	-21006.19%
Basic Earnings Per Share	-$2.28	-$1.79	-$1.57
Diluted Earnings Per Share	-$2.283M	-$1.79	-$1.57
COMMON SHARES
Basic Shares Outstanding	85.66K		75.51M
Diluted Shares Outstanding	85.66K

Balance Sheet

Concept	2021 Q3	2020 Q3	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$430.3M	$728.2M	$832.8M
YoY Change	-40.91%	67.79%	188.07%
Cash & Equivalents	$283.7M	$415.6M	$317.3M
Short-Term Investments	$146.6M	$312.6M	$515.5M
Other Short-Term Assets	$39.92M	$14.20M	$21.00M
YoY Change	181.11%	477.82%	525.75%
Inventory	$1.677M
Prepaid Expenses
Receivables	$3.500M
Other Receivables	$0.00
Total Short-Term Assets	$475.4M	$742.3M	$853.8M
YoY Change	-35.95%	64.52%	176.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$27.44M	$25.10M	$15.40M
YoY Change	9.32%	1475.85%	970.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$22.82M	$900.0K	$900.0K
YoY Change	2435.89%	280.53%	332.96%
Total Long-Term Assets	$50.26M	$26.00M	$16.30M
YoY Change	93.32%	71.48%	96.59%
TOTAL ASSETS
Total Short-Term Assets	$475.4M	$742.3M	$853.8M
Total Long-Term Assets	$50.26M	$26.00M	$16.30M
Total Assets	$525.7M	$768.3M	$870.1M
YoY Change	-31.58%	64.75%	174.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.984M	$11.10M	$9.900M
YoY Change	-55.1%	-6.22%	-28.32%
Accrued Expenses	$69.85M	$60.77M	$45.40M
YoY Change	14.94%	99.68%	124.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$15.33M
YoY Change
Total Short-Term Liabilities	$94.24M	$75.30M	$58.00M
YoY Change	25.15%	68.94%	62.96%
LONG-TERM LIABILITIES
Long-Term Debt	$189.6M	$353.8M	$348.8M
YoY Change	-46.41%	151.64%	5105.97%
Other Long-Term Liabilities	$299.2M	$233.5M	$231.2M
YoY Change	28.12%	93300.0%	92380.0%
Total Long-Term Liabilities	$488.8M	$587.3M	$580.0M
YoY Change	-16.78%	234820.0%	231900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$94.24M	$75.30M	$58.00M
Total Long-Term Liabilities	$488.8M	$587.3M	$580.0M
Total Liabilities	$583.0M	$662.5M	$638.0M
YoY Change	-12.0%	1378.06%	304.78%
SHAREHOLDERS EQUITY
Retained Earnings		-$1.005B
YoY Change
Common Stock		$8.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$57.33M	$105.8M	$232.1M
YoY Change
Total Liabilities & Shareholders Equity	$525.7M	$768.3M	$870.1M
YoY Change	-31.58%	64.74%	174.74%

Cashflow Statement

Concept	2021 Q3	2020 Q3	2020 Q2
OPERATING ACTIVITIES
Net Income	-$195.6M	-$135.7M	-$118.6M
YoY Change	44.12%	94.34%	66.85%
Depreciation, Depletion And Amortization	$282.0K	$190.0K	$90.00K
YoY Change	48.42%	216.67%	80.0%
Cash From Operating Activities	-$168.6M	-$99.83M	-$94.29M
YoY Change	68.91%	86.28%	136.26%
INVESTING ACTIVITIES
Capital Expenditures	-$352.0K	-$3.740M	-$530.0K
YoY Change	-90.59%	695.74%	178.95%
Acquisitions
YoY Change
Other Investing Activities	$180.0M	$202.5M	-$287.3M
YoY Change	-11.11%
Cash From Investing Activities	$179.6M	$198.8M	-$287.8M
YoY Change	-9.62%	-42389.36%	151378.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.120M	920.0K	281.7M
YoY Change	130.43%	-99.54%	587.67%
NET CHANGE
Cash From Operating Activities	-168.6M	-99.83M	-94.29M
Cash From Investing Activities	179.6M	198.8M	-287.8M
Cash From Financing Activities	2.120M	920.0K	281.7M
Net Change In Cash	13.14M	99.85M	-100.4M
YoY Change	-86.84%	-31.09%	-11777.91%
FREE CASH FLOW
Cash From Operating Activities	-$168.6M	-$99.83M	-$94.29M
Capital Expenditures	-$352.0K	-$3.740M	-$530.0K
Free Cash Flow	-$168.3M	-$96.09M	-$93.76M
YoY Change	75.12%	80.89%	136.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q1	apls	Accounting Standards Update Description AccountingStandardsUpdateDescription	ASU 2020-06
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y10M13D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M28D
	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5650000
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	646000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6273000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	646000
CY2021Q3	apls	Operating Cost Of Sales OperatingCostOfSales	149000
	apls	Operating Cost Of Sales OperatingCostOfSales	149000
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	87733000
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45763000
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	36991000
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	133645000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-343847000
	apls	Loss On Conversion Of Debt LossOnConversionOfDebt	100589000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-42483000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-62939000
CY2020Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	670000
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	381000
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	3970000
CY2021Q3	apls	Interest Expense Nonoperating InterestExpenseNonoperating	2282000
CY2020Q3	apls	Interest Expense Nonoperating InterestExpenseNonoperating	9499000
	apls	Interest Expense Nonoperating InterestExpenseNonoperating	10223000
	apls	Interest Expense Nonoperating InterestExpenseNonoperating	20327000
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-117000
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1366000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000
	us-gaap	Net Income Loss NetIncomeLoss	-423139000
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-430000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	19000
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-230000
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-137788000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	122000
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1658000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1912000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1727000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-181000
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2088000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1893000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1605000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-195752000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-600314000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-424744000
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.28
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.79
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.31
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.65
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85661000
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	75628000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81846000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	74925000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	204557000
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	162258000
CY2021Q1	apls	Adjustments To Additional Paid In Capital Forfeiture Of Accrued Interest In Exchange Of Convertible Notes AdjustmentsToAdditionalPaidInCapitalForfeitureOfAccruedInterestInExchangeOfConvertibleNotes	1668000
CY2021Q1	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-956000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16439000
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	79000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-183659000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1582000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	51658000
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7062000
CY2021Q2	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-233000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17722000
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1698000
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-35000
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	258105000
CY2021Q3	apls	Adjustments To Additional Paid In Capital Forfeiture Of Accrued Interest In Exchange Of Convertible Notes AdjustmentsToAdditionalPaidInCapitalForfeitureOfAccruedInterestInExchangeOfConvertibleNotes	2503000
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2480000
CY2021Q3	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-362000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17194000
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-25000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-195571000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-156000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-57325000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	34229000
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	381458000
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1674000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9294000
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1394000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-168822000
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	258997000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	35000
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1355000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11489000
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-842000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	122147000
CY2020Q2	apls	Adjustments To Additional Paid In Capital Purchase Of Capped Call Transactions And Associated Costs AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsAndAssociatedCosts	-43112000
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	521000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-118617000
CY2020Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	161000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	232064000
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1127000
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12099000
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-430000
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	-1662000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-135700000
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1658000
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	105840000
	us-gaap	Profit Loss ProfitLoss	-598421000
	us-gaap	Profit Loss ProfitLoss	-423139000
	us-gaap	Share Based Compensation ShareBasedCompensation	51355000
	us-gaap	Share Based Compensation ShareBasedCompensation	32882000
	apls	Loss On Conversion Of Debt LossOnConversionOfDebt	100589000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-42483000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-62939000
	apls	Forfeiture Of Accrued Interest In Exchange Of Convertible Notes ForfeitureOfAccruedInterestInExchangeOfConvertibleNotes	4171000
	apls	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	110000
	apls	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	209000
	us-gaap	Depreciation Depreciation	1006000
	us-gaap	Depreciation Depreciation	370000
	apls	Amortization Of Discounts For Convertible Notes Net Of Financing Costs AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts	821000
	apls	Amortization Of Discounts For Convertible Notes Net Of Financing Costs AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts	10476000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2618000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1677000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5862000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-8503000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-6677000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	627000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	3956000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	519000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3213000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2392000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-42092000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4047000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-450627000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-302467000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1084000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4711000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	171280000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	567187000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	335000000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	255000000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	162636000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-316898000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	381423000
	apls	Proceeds From Payments For Development Derivative Liability ProceedsFromPaymentsForDevelopmentDerivativeLiability	-4000000
	apls	Proceeds From Payments For Development Derivative Liability ProceedsFromPaymentsForDevelopmentDerivativeLiability	20000000
	apls	Payments For Capped Call Transactions And Associated Costs PaymentsForCappedCallTransactionsAndAssociatedCosts	43112000
	apls	Proceeds From Issuance Of Convertible Notes Net Of Issuance Costs ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCosts	322874000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12131000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4155000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1698000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	521000
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1551000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8278000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	685861000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2024000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1666000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-281737000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	64830000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	567045000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	351985000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	285308000
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	416815000
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	283745000
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	415560000
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	1563000
CY2020Q3	us-gaap	Restricted Cash RestrictedCash	1255000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	285308000
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	416815000
	us-gaap	Interest Paid Net InterestPaidNet	10265000
	us-gaap	Interest Paid Net InterestPaidNet	12929000
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	327276000
	us-gaap	Nature Of Operations NatureOfOperations	<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:2.5%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:2.5%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-weight:normal;color:#000000;"/><span style="font-size:10pt;color:#000000;">Nature of Organization and Operations </span></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Apellis Pharmaceuticals, Inc. (the “Company”) is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was incorporated in September 2009 under the laws of the State of Delaware and has its principal office in Waltham, Massachusetts.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s operations since inception have been limited to organizing and staffing the Company, acquiring rights to product candidates, business planning, raising capital and developing and commercializing its product candidates. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common in the biotechnology industry including, but not limited to, raising additional capital, development by its competitors of new technological innovations, its ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval of products, its ability to successfully commercialize its products, market acceptance of the Company’s products, protection of proprietary technology, healthcare cost containment initiatives, and compliance with governmental regulations, including those of the U.S. Food and Drug Administration (“FDA”). Additionally, the Company is subject to risks arising from the Coronavirus Disease 2019 (COVID-19) pandemic, which could have adverse effects upon its business and operations, including on its ability to initiate, conduct and complete clinical trials, the timing of the initiation of planned and future clinical trials, regulatory activities and commercialization of its products.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:3.4%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Adoption of ASU 2020-06 Debt – Debt with Conversion and Other Options (Subtopic 470-20)</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2021, the Company early adopted ASU 2020-06, <span style="font-style:italic;">Debt – Debt with Conversion and Other Options (Subtopic 470-20) </span>which<span style="font-style:italic;"> </span>reduces complexity in applying GAAP to certain financial instruments with characteristics of liability and equity. The ASU removes the guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The ASU further revises the guidance to require entities to calculate diluted earnings per share for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted earnings per share when an instrument may be settled in cash or shares. The impact of the adoption of the statement increased net debt outstanding and decreased net equity by $149.7 million as of January 1, 2021. Of the $149.7 million decrease to net equity, $16.0 million was recorded to retained earnings. See Note 7, Long Term Debt for additional information.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:3.4%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Notes Exchange </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="font-size:12pt;"> </span>January 2021, the Company entered into separate, privately negotiated exchange agreements to modify the conversion terms with certain holders of its convertible notes issued in September 2019 (the “2019 Convertible Notes”). Under the terms of these exchange agreements, the holders exchanged approximately $126.1 million in aggregate principal amount of 2019 Convertible Notes held by them for an aggregate of 3,906,869 shares of common stock issued by the Company. The Company also issued 69,491 shares for settlement of issuance costs paid to the Company’s advisor. The Company recognized a total loss on conversion of debt in the unaudited condensed consolidated statement of operations of $39.5 million. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the Company entered into separate, privately negotiated exchange agreements to modify the conversion terms with certain holders of the 2019 Convertible Notes and the 2020 Convertible Notes issued in May 2020 (the “2020 Convertible Notes”, and together with the 2019 Convertible Notes, the “Convertible Notes”). Under the terms of these exchange agreements, the holders exchanged approximately $201.1 million in aggregate principal amount of Convertible Notes held by them for an aggregate of 5,992,217 shares of common stock issued by the Company. The Company also has agreed to issue 78,419 shares for settlement of issuance costs paid to the Company’s advisor. The Company recognized a total loss on conversion of debt in the unaudited condensed consolidated statement of operations of $61.1 million for the three months ended September 2021.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized a total loss on the conversion of debt of $100.6 million in the unaudited condensed statement of operations for the nine months ended September 30, 2021. As of September 30, 2021, the Company held in treasury Convertible Notes </p> <p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">327.2</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million which notes have not been cancelled. See Note 7, Long Term Debt for additional information</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:3.4%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Going Concern </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of November 8, 2021, the date of issuance of these unaudited condensed consolidated financial statements, the Company believes that its cash and cash equivalents and marketable securities of $430.3<span style="font-size:12pt;"> </span>million as of September 30, 2021, together with anticipated revenue from sales of EMPAVELI and development reimbursement payments from Swedish Orphan Biovitrum AB (Publ) (“Sobi”), will not be sufficient to fund its operations and capital expenditure requirements for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements which raises substantial doubt about our ability to continue as a going concern. <span style="color:#000000;">The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span> </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has generated only limited revenues to date from product sales and has not achieved profitability. The Company’s plans to meet its short-term and longer-term operating cash flow requirements include: (1) obtaining additional debt or equity financing on terms that are favorable to the Company (2) achieving its projected revenues from sales of EMPAVELI, (3) entering into collaborative agreements with strategic partners to obtain funding, and (4) succeeding in its future operations. If the Company is not able to obtain the required funding for its operations, or to obtain funding on a timely basis on terms that are<span style="color:#000000;"> favorable to the Company, or to achieve its projected revenue, it could be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts and its business could be materially harmed. </span></p>
CY2021Q3	apls	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	430300000
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.81%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.44%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.44%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="color:#000000;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents, restricted cash, marketable securities and account receivables. The Company’s cash, cash equivalents, restricted cash and marketable securities are concentrated at financial institutions that management believes are creditworthy. Marketable securities consist of treasury notes and certificates of deposit. The Company's investment policy includes guidelines on the quality of the institutions and </span></p> <p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;">financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentrations of credit risk.</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.44%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company has entered into distribution agreements with a limited number of SPs and SDs, and all of the Company’s product sales will be to these customers. </span>The Company routinely assesses the creditworthiness of its customers. The Company does not require collateral. <span style="Background-color:#FFFFFF;">For the quarter ended September 30, 2021, a small number of customers represented all of the Company’s product revenue and accounts receivable balance at September 30, 2021. The Company </span>has not experienced any losses related to the accounts receivables and no allowance for credit losses has been recorded for the Company's accounts receivable balance as of September 30, 2021.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company does not currently have any of its own manufacturing facilities, and therefore it depends on an outsourced manufacturing strategy for the production of EMPAVELI for commercial use and for the production of its product candidates for clinical trials. The Company has contracts in place with one third-party manufacturer of commercial drug product and one third-party manufacturer of the drug substance that is approved for the production of EMPAVELI active pharmaceutical ingredient (API). Although there are potential sources of supply other than the Company’s existing suppliers, any new supplier would be required to qualify under applicable regulatory requirements.</span></p>
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2021Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1600000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1300000
CY2021Q3	apls	Obsolete Inventory ObsoleteInventory	0
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3500000
CY2021Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1400000
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	300000
CY2020Q4	us-gaap	Inventory Net InventoryNet	0
CY2021Q3	apls	Prepaid Research And Development Cost Current PrepaidResearchAndDevelopmentCostCurrent	12000000.0
CY2020Q4	apls	Prepaid Research And Development Cost Current PrepaidResearchAndDevelopmentCostCurrent	8000000.0
CY2021Q3	apls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	28670000
CY2020Q4	apls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	47879000
CY2020Q4	apls	Accrued License Fees Current AccruedLicenseFeesCurrent	25050000
CY2021Q3	apls	Accrued Payroll Liabilities Current AccruedPayrollLiabilitiesCurrent	27124000
CY2020Q4	apls	Accrued Payroll Liabilities Current AccruedPayrollLiabilitiesCurrent	22896000
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14053000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	16110000
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	69847000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	111935000
CY2020Q4	apls	Development Derivative Liabilities Gross DevelopmentDerivativeLiabilitiesGross	257868000
CY2019Q4	apls	Development Derivative Liabilities Gross DevelopmentDerivativeLiabilitiesGross	134839000
CY2020Q1	apls	Minimum Payment Of Additional Funding Amount MinimumPaymentOfAdditionalFundingAmount	20000000
CY2021Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-17084000
CY2020Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-68406000
CY2021Q1	apls	Development Derivative Liabilities Gross DevelopmentDerivativeLiabilitiesGross	274952000
CY2020Q1	apls	Development Derivative Liabilities Gross DevelopmentDerivativeLiabilitiesGross	223245000
CY2021Q2	apls	Minimum Payment Of Additional Funding Amount MinimumPaymentOfAdditionalFundingAmount	-4000000
CY2021Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-21180000
CY2020Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2770000
CY2021Q2	apls	Development Derivative Liabilities Gross DevelopmentDerivativeLiabilitiesGross	292132000
CY2020Q2	apls	Development Derivative Liabilities Gross DevelopmentDerivativeLiabilitiesGross	220475000
CY2020Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2697000
CY2020Q3	apls	Development Derivative Liabilities Gross DevelopmentDerivativeLiabilitiesGross	217778000
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company enters into lease agreements with terms generally ranging from 2-7 years. Some of the Company’s lease agreements include Company options to extend the lease on a month-to-month basis or for set periods for up to five years. Many of these leases also include options to terminate the leases within one year or per other contractual terms. Renewal and termination options were generally not included in the lease term for the Company’s existing operating leases.
	apls	Lessee Operating Lease Maximum Term Of Options To Terminate Lease LesseeOperatingLeaseMaximumTermOfOptionsToTerminateLease	P1Y
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20930000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17719000
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	22222000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	18902000
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0771
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0774
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1400000
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1100000
	us-gaap	Operating Lease Cost OperatingLeaseCost	4200000
	us-gaap	Operating Lease Cost OperatingLeaseCost	3100000
	us-gaap	Operating Lease Payments OperatingLeasePayments	4476000
	us-gaap	Operating Lease Payments OperatingLeasePayments	3322000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5675000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6664000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1436000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5561000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5625000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4862000
CY2021Q3	apls	Lessee Operating Lease Liability Payments Due Year Four And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter	9261000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	26745000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4523000
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	22222000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1503000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-209000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-181000
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1164000
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-681000
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2088000
	apls	Minimum Percentage Of Tax Position Likelihood Of Being Realized Upon Examination By Taxing Authorities MinimumPercentageOfTaxPositionLikelihoodOfBeingRealizedUponExaminationByTaxingAuthorities	0.50
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2020Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2020Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2021Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2021Q3	apls	Contra Research And Development Expense ContraResearchAndDevelopmentExpense	6400000
	apls	Contra Research And Development Expense ContraResearchAndDevelopmentExpense	23600000
CY2020Q4	apls	Contract Research And Development Receivable ContractResearchAndDevelopmentReceivable	43000000.0
CY2020Q4	apls	Contract Research And Development Current ContractResearchAndDevelopmentCurrent	25000000.0
CY2020Q4	apls	Contract Research And Development Long Term Assets ContractResearchAndDevelopmentLongTermAssets	18000000.0
CY2021Q3	apls	Contract Research And Development Current ContractResearchAndDevelopmentCurrent	20000000.0
CY2021Q3	apls	Contract Research And Development Long Term Assets ContractResearchAndDevelopmentLongTermAssets	21600000
CY2021Q3	apls	Estimated Termination Costs And Other Fees EstimatedTerminationCostsAndOtherFees	2400000
	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	0
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18909000
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25784000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18909000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25784000

Files In Submission

Name	View Source	Status
0001564590-21-055235-index-headers.html	Edgar Link	pending
0001564590-21-055235-index.html	Edgar Link	pending
0001564590-21-055235.txt	Edgar Link	pending
0001564590-21-055235-xbrl.zip	Edgar Link	pending
apls-10q_20210930.htm	Edgar Link	pending
apls-10q_20210930_htm.xml	Edgar Link	completed
apls-20210930.xsd	Edgar Link	pending
apls-20210930_cal.xml	Edgar Link	unprocessable
apls-20210930_def.xml	Edgar Link	unprocessable
apls-20210930_lab.xml	Edgar Link	unprocessable
apls-20210930_pre.xml	Edgar Link	unprocessable
apls-ex311_9.htm	Edgar Link	pending
apls-ex312_6.htm	Edgar Link	pending
apls-ex321_8.htm	Edgar Link	pending
apls-ex322_7.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APLS
Apellis Pharmaceuticals, Inc. Stock $apls

2021 Q3 Form 10-Q Financial Statement

#000156459021055235 Filed on November 08, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APLS Apellis Pharmaceuticals, Inc. Stock $apls

2021 Q3 Form 10-Q Financial Statement

#000156459021055235 Filed on November 08, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APLS
Apellis Pharmaceuticals, Inc. Stock $apls